A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...
Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...
Prostate cancer relies on genetic "switches," called enhancers, that can turn on tumor-promoting genes. Researchers at the ...
In hormone-sensitive prostate cancer, an alternative dosing of docetaxel plus Nubeqa and ADT was associated with improvements in side effect rates.
Bayer AG (($BAYRY)) announced an update on their ongoing clinical study. Bayer AG is conducting a Phase 1 clinical study titled ‘A Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback